Drug Delivery Systems in India: A Deep Patent Bench, Nascent Startup Activity

What it is

Drug delivery systems are engineered formulations or devices that control how a pharmaceutical compound is released, absorbed, and distributed in the body. They go far beyond simple pills, using routes like oral, injectable, transdermal, and inhalation to target specific tissues, sustain release over time, or respond to physiological cues such as pH or temperature.

The goal is to improve a drug’s safety and efficacy—getting the right dose to the right place at the right time. Advanced carriers like nanoparticles, liposomes, and smart implants can bypass biological barriers, protect fragile molecules (e.g., mRNA), and reduce side effects by avoiding healthy tissue.

This field underpins modern treatments for cancer, diabetes, cardiovascular disease, and vaccines. It sits at the intersection of materials science, pharmacology, and device engineering, making it a classic deep-tech domain with high IP defensibility.

The value chain

• Upstream – R&D and Formulation: Design of drug carriers, excipients, and delivery mechanisms; preclinical and clinical testing. High IP concentration and long development timelines create strong moats.
• Midstream – Device/System Manufacturing: Production of delivery devices (injectors, inhalers, patches) and advanced formulations (liposomes, nanoparticles). Requires specialized aseptic manufacturing and quality control; scale-up is capital-intensive.
• Midstream – Assembly and Packaging: Aseptic filling, device assembly, and stability packaging. Often integrated with manufacturing; blow-fill-seal technology is a key differentiator.
• Downstream – Distribution and Logistics: Temperature-controlled storage and transport to pharmacies, hospitals, and clinics. Cold-chain expertise is critical for biologics and mRNA-based systems.
• End-Use – Administration and Monitoring: Use by patients or healthcare providers, including self-administration training and adherence tools. Wearables and connected devices are adding a services layer here.
• Value pools: The highest margins and defensibility cluster in the upstream R&D and midstream device manufacturing stages, where proprietary formulations and delivery mechanisms are patented. India’s strength in generic pharma manufacturing gives it a natural foothold in midstream scale-up, but upstream innovation is where deep-tech startups can carve out IP.

Where it's heading

Globally, the drug delivery systems market was valued at USD 47.72 billion in 2025, growing at a CAGR of 4.56% (Fortune Business Insights). The broader advanced drug delivery market is estimated at USD 295.71 billion in 2026 (Mordor Intelligence), while the electronic drug delivery segment alone reached USD 11.95 billion in 2024 (Grand View Research). India-specific market sizing is not publicly available, but the country’s large pharmaceutical manufacturing base and growing biologics pipeline make it a significant potential adopter.

• Self-administration and wearables: Insulin pumps, auto-injectors, and connected inhalers are shifting care from clinics to homes, driven by chronic disease prevalence (Grand View Research).
• AI-driven formulation: Machine learning is being used to personalize drug release profiles and optimize carrier design, compressing R&D timelines (MedTech Outlook).
• Nanocarrier boom: Lipid nanoparticles and liposomes are becoming the backbone of mRNA and siRNA delivery, spurred by the success of COVID-19 vaccines (Mordor Intelligence).
• Smart implants: Stimuli-responsive implants that automate drug release based on real-time physiological signals are moving from lab to clinic (Mordor Intelligence).
• India-specific: Pharma startup funding in India dropped sharply to $25.3 million by May 2025, reflecting a broader funding winter, but regulatory reforms propose cutting clinical trial approval times from 90 to 45 days, which could accelerate delivery system development (Express Pharma, RAPS).

The opportunity in India

Our data maps 636 patents to drug delivery systems in India, with steady filing activity over the years. Yet only 18 deep-tech companies in our dataset explicitly reference drug delivery in their profiles—a signal that commercial translation is still thin. Meanwhile, 88 patent-holding startups appear in our data, though many are individual inventors rather than incorporated entities, pointing to a large pool of uncommercialized IP.

This gap between invention and company formation is the white space. India’s established pharma manufacturing ecosystem can provide scale-up partners, but the upstream innovation—novel nanocarriers, smart devices, AI-optimized formulations—remains under-exploited by startups. The recent regulatory push to streamline clinical trials could lower the barrier for early-stage ventures.

Funding for drug delivery specifically is not isolated in our data, but the broader health-life-sciences sector has seen 973 companies raise a combined $2.6 billion, with a median round of $1 million. This suggests capital is available for life sciences, but drug delivery startups may need to position themselves at the convergence of device, formulation, and digital health to attract investment.

India signal: patents, startups, capital

Patent stock: 636 patents matched to drug delivery systems in our dataset. Filing momentum is steady; the latest two years are understated due to the 18-month publication lag, so no decline should be inferred.

Patent-holding startups: 88 startups in our data hold at least one patent in this space. The list includes many individual inventors (e.g., multiple entries for Mohit Kumar across cities), suggesting a significant portion of IP resides with solo inventors or academic incubators like Chitkara Innovation Incubator Foundation (11 patents).

Company activity: Our dataset contains 18 deep-tech companies that explicitly mention drug delivery systems in their profiles—a lower-bound signal. Examples include Novelty Healthshine (Ahmedabad), MK Quantum Technologies (Bengaluru), Phytonanos Drug Technologies (Kanchipuram), and Nomisma Healthcare (Vadodara). This is not an exhaustive census; other firms may operate without using the exact phrase.

Sector funding: The health-life-sciences sector overall has 973 funded companies, raising $2.6 billion total (median $1.0 million). Notable funded players like Enveda ($517M, AI-driven drug discovery) and Pandorum Technologies ($52.1M, tissue engineering) are in the broader sector but not specifically drug delivery companies. Drug delivery-focused funding data is not separately tracked in our dataset.

In our data

Sources

• Advances in drug delivery systems, challenges and future ... ↗
• Drug Delivery Systems: An Overview ↗
• Drug Delivery for Medical Treatment ↗
• A comprehensive guide to the pharmaceutical supply chain ↗
• Supply Chain Challenges in Pharmaceutical Manufacturing ... ↗
• Pharma Supply Chain: A Comprehensive Guide ↗
• Electronic Drug Delivery Systems Market Size Report, 2030 ↗
• Advanced Drug Delivery Systems Market Size, Report Analysis 2031 ↗